The Impact of Hemodialysis Frequency and Duration on Blood Pressure Management and Quality of Life in End-Stage Renal Disease Patients

Mohammad Ali Shafiee, Pouyan Chamanian, Pouyan Shaker, Yasmin Shahideh, Behrooz Broumand, Mohammad Ali Shafiee, Pouyan Chamanian, Pouyan Shaker, Yasmin Shahideh, Behrooz Broumand

Abstract

Cardiovascular complications are the most prominent causes of morbidity and mortality among chronic kidney disease (CKD) and end-stage renal disease (ESRD) patients undergoing standard hemodialysis (HD) therapy. Cardiovascular disease risk is increased significantly through persistent hypertension and blood pressure (BP) fluctuation, which are the most common complications of CKD. It was hypothesized that an extended approach with lengthier and more frequent dialysis sessions, referred to in this paper as "extended hemodialysis" (EHD), can potentially lower and stabilize blood pressure, and consequently reduce the rate of morbidity and mortality. A greater reduction of volume (salt and water) with higher frequency can improve patient quality of life (QOL). Eleven papers, including clinical trials and systematic reviews were chosen and analyzed. The extracted data was used to evaluate the change in blood pressure levels between standard HD and EHD. Overall, the studies showed that EHD resulted in improved blood pressure management; therefore, we concluded that there will be a decrease in cardiovascular disease risk, stroke, and morbidity and mortality rate. There will be also an improvement in patient QOL due to beneficial effects of the EHD.

Keywords: End Stage Renal Disease; blood pressure; hemodialysis; quality of life.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Hill N.R., Fatoba S.T., Oke J.L., Hirst J.A., O’Callaghan C.A., Lasserson D.S., Hobbs F.D. Global prevalence of chronic kidney disease—A systematic review and meta-analysis. PLoS ONE. 2016;11:e0158765. doi: 10.1371/journal.pone.0158765.
    1. U.S. Renal Data System . USRDS 2013 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD, USA: 2014.
    1. Greer J.W. End stage renal disease and medicare. Health Care Financ. Rev. 2013;24:1–5.
    1. United States Renal Data System . 2016 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD, USA: 2016.
    1. Susantitaphong P., Koulouridis I., Balk E.M., Madias N.E., Jaber B.L. Effect of frequent or extended hemodialysis on cardiovascular parameters: A meta-analysis. Am. J. Kidney Dis. 2012;59:689–699. doi: 10.1053/j.ajkd.2011.12.020.
    1. Ranganathan D., John G.T. Nocturnal hemodialysis. Indian J. Nephrol. 2012;22:323–332. doi: 10.4103/0971-4065.103905.
    1. Ikonomou M., Skapinakis P., Balafa O., Eleftheroudi M., Damigos D., Siamopoulos K.C. The impact of socioeconomic factors on quality of life of patients with chronic kidney disease in Greece. J. Ren. Care. 2015;41:239–246. doi: 10.1111/jorc.12132.
    1. Feroze U., Noori N., Kovesdy C.P., Molnar M.Z., Martin D.J., Reina-Patton A., Benner D., Bross R., Norris K.C., Kopple J.D., et al. Quality-of-life and mortality in hemodialysis patients: Roles of race and nutritional status. Clin. J. Am. Soc. Nephrol. 2011;6:1100–1111. doi: 10.2215/CJN.07690910.
    1. Edalat-Nejad M., Qlich-Khani M. Quality of life and sleep in hemodialysis patients. Saudi J. Kidney Dis. Transplant. 2013;24:514–518. doi: 10.4103/1319-2442.111031.
    1. Chandrashekar A., Ramakrishnan S., Rangarajan D. Survival analysis of patients on maintenance hemodialysis. Indian J. Nephrol. 2014;24:206–213. doi: 10.4103/0971-4065.132985.
    1. Stern A., Sachdeva S., Kapoor R., Singh J., Sachdeva S. High blood pressure in dialysis patients: Cause, pathophysiology, influence on morbidity, mortality and management. J. Clin. Diagn. Res. 2014;8:ME01–ME04.
    1. Inrig J.K. Antihypertensive agents in hemodialysis patients: A current perspective. Semin. Dial. 2010;23:290–297. doi: 10.1111/j.1525-139X.2009.00697.x.
    1. Tedla F.M., Brar A., Browne R., Brown C. Hypertension in chronic kidney disease: Navigating the evidence. Int. J. Hypertens. 2011;2011:132405. doi: 10.4061/2011/132405.
    1. Al-Dadah A., Omran J., Nusair M.B., Dellsperger K.C. Cardiovascular mortality in dialysis patients. Adv. Perit. Dial. 2012;28:56–59.
    1. Shafi T., Waheed S., Zager P.G. Hypertension in hemodialysis patients: An opinion-based update. Semin. Dial. 2014;27:146–153. doi: 10.1111/sdi.12195.
    1. Nesrallah G., Suri R., Moist L., Kortas C., Lindsay R.M. Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am. J. Kidney Dis. 2003;42(Suppl. 1):13–17. doi: 10.1016/S0272-6386(03)00532-8.
    1. Ramdeen G., Tzamaloukas A.H., Malhotra D., Leger A., Murata G.H. Estimates of interdialytic sodium and water intake based on the balance principle: Differences between nondiabetic and diabetic subjects on hemodialysis. ASAIO J. 1998;44:812–817. doi: 10.1097/00002480-199811000-00009.
    1. Hecking M., Karaboyas A., Antlanger M., Saran R., Wizemann V., Chazot C., Rayner H., Hörl W.H., Pisoni R.L., Robinson B.M., et al. Significance of interdialytic weight gain versus chronic volume overload: Consensus opinion. Am. J. Nephrol. 2013;38:78–90. doi: 10.1159/000353104.
    1. Taniyama Y. Management of hypertension for patients undergoing dialysis therapy. Ren. Replace. Ther. 2016;2:21. doi: 10.1186/s41100-016-0034-2.
    1. Morishita Y., Kusano E., Nagata D. Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis. Open Cardiovasc. Med. J. 2014;8:6–11. doi: 10.2174/1874192401408010006.
    1. Choi H.Y., Ha S.K. Potassium balances in maintenance hemodialysis. Electrolytes Blood Press. 2013;11:9–16. doi: 10.5049/EBP.2013.11.1.9.
    1. Liu F., Sun Y., Xu T., Sun L., Liu L., Sun W., Feng X., Ma J., Wang L., Yao L. Effect of nocturnal hemodialysis versus conventional hemodialysis on end-stage renal disease: A meta-analysis and systematic review. PLoS ONE. 2017;12:e0169203. doi: 10.1371/journal.pone.0169203.
    1. Jindal K., Chan C.T., Dezial C., Hirsch D., Soroka S.D., Tonelli M., Culleton B.F. CHAPTER 5: Frequent and sustained hemodialysis. J. Am. Soc. Nephrol. 2006;17:S24–S27.
    1. Ipema K.J., Kuipers J., Westerhuis R., Gaillard C.A., van der Schans C.P., Krijnen W.P., Franssen C.F. Causes and Consequences of Interdialytic weight gain. Kidney Blood Press. Res. 2016;41:710–720. doi: 10.1159/000450560.
    1. Agarwal R., Andersen M.J., Pratt J.H. On the importance of pedal edema in hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2008;3:153–158. doi: 10.2215/CJN.03650807.
    1. Murtagh F.E., Addington-Hall J., Higginson I.J. The prevalence of symptoms in end-stage renal disease: A systematic review. Adv. Chronic Kidney Dis. 2007;14:82–99. doi: 10.1053/j.ackd.2006.10.001.
    1. Spanner E., Suri R., Heidenheim A.P., Lindsay R.M. The impact of quotidian hemodialysis on nutrition. Am. J. Kidney Dis. 2003;42(Suppl. 1):30–35. doi: 10.1016/S0272-6386(03)00535-3.
    1. Kroeker A., Clark W.F., Heidenheim A.P., Kuenzig L., Leitch R., Meyette M., Muirhead N., Ryan H., Welch R., White S. An operating cost comparison between conventional and home quotidian hemodialysis. Am. J. Kidney Dis. 2003;42(Suppl. 1):49–55. doi: 10.1016/S0272-6386(03)00538-9.
    1. Blagg C.R. Quotidian dialysis: The London, Ontario experience. Am. J. Kidney Dis. 2003;42(Suppl. 1):1–2. doi: 10.1016/S0272-6386(03)00529-8.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere